← All trials
NCT04810910
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 30, 2021
- Primary completion
- Mar 30, 2025
- Completion date
- Mar 30, 2025
- First posted
- Mar 23, 2021
- Last posted
- Nov 16, 2021
- Enrollment
- 20
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Zhejiang UniversityLead sponsor
- Zhejiang UniversityReponsible party - principal investigator
- Zhejiang UniversityOverall official - principal investigator
- Hangzhou Neoantigen Therapeutics Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.